Cargando…

Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial

BACKGROUND: Current guidelines recommend treatment with capecitabine and bevacizumab for patients (pts) with non-resectable metastatic colorectal cancer (mCRC), although clinical data in this particular patient group are lacking. METHODS: Previously untreated patients with non-resectable mCRC were t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stein, Alexander, Kretzschmar, Albrecht, Behringer, Dirk, Wolff, Thomas, Zimber, Joachim, Hegewisch-Becker, Susanna, Kettner, Erika, Pflüger, Karl-Heinz, Kirsch, Andreas, Arnold, Dirk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850951/ https://www.ncbi.nlm.nih.gov/pubmed/24090011 http://dx.doi.org/10.1186/1471-2407-13-454

Ejemplares similares

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
por: Hoehler, T, et al.
Publicado: (2013)

Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients—Analysis of the Phase III AIO KRK-0207 Trial
por: Stintzing, Sebastian, et al.
Publicado: (2018)

A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial
por: Giessen, Clemens, et al.
Publicado: (2011)

Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial
por: Stintzing, S, et al.
Publicado: (2011)

Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials
por: Noepel-Duennebacke, Stefanie, et al.
Publicado: (2021)

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
por: Stintzing, S, et al.
Publicado: (2019)

Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)
por: Modest, Dominik Paul, et al.
Publicado: (2022)

PA01.05. Formulation & Evaluation of herbomineral natural hair colorant
por: Wanjari, Anita S., et al.
Publicado: (2012)

FIRE-9 – PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer
por: Raschzok, Nathanael, et al.
Publicado: (2022)

EMT-Related Genes Have No Prognostic Relevance in Metastatic Colorectal Cancer as Opposed to Stage II/III: Analysis of the Randomised, Phase III Trial FIRE-3 (AIO KRK 0306; FIRE-3)
por: Pretzsch, Elise, et al.
Publicado: (2022)

Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)
por: Tintelnot, Joseph, et al.
Publicado: (2020)

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
por: von Einem, J. C., et al.
Publicado: (2014)

Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306
por: Hofmann, Felix O., et al.
Publicado: (2022)

Aios in coronatijd
por: Maria Greijn, Claudia, et al.
Publicado: (2020)

Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)
por: Heinrich, K., et al.
Publicado: (2023)

OA01.05. Effectiveness of simple and logical treatment in complete disc prolapse
por: Parthasarathy, R
Publicado: (2013)

Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer
por: Sommerhäuser, G., et al.
Publicado: (2022)

Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial
por: Welt, A., et al.
Publicado: (2016)

P01.05. Increase in blood flow associated with traditional chinese medicine therapies
por: Lin, S, et al.
Publicado: (2012)

EHMTI-0105. CGRP and VIP levels as predictors of efficacy of onabotulinumtoxin type A in chronic migraine
por: Cernuda-Morollón, E, et al.
Publicado: (2014)

Monte Carlo simulations of Higgs-boson production at the LHC with the KrkNLO method
por: Jadach, S., et al.
Publicado: (2016)

NLO Corrections to Hard Process in Parton Shower MC - KrkNLO Method
por: Jadach, S, et al.
Publicado: (2015)

AIOS proceedings: A response
por: Rajendran, Babu
Publicado: (2009)

19. AIO-Herbstkongress 2022
Publicado: (2023)

Antimicrobial and Antioxidant Polyketides from a Deep-Sea-Derived Fungus Aspergillus versicolor SH0105
por: Yang, Lu-Jia, et al.
Publicado: (2020)

Siphophage 0105phi7-2 of Bacillus thuringiensis: Novel Propagation, DNA, and Genome-Implied Assembly
por: Roberts, Samantha M., et al.
Publicado: (2023)

Matching NLO QCD with parton shower in Monte Carlo scheme — the KrkNLO method
por: Jadach, S., et al.
Publicado: (2015)

Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer
por: Dellas, Kathrin, et al.
Publicado: (2013)

OA01.05. Role of prabhakara vati and lekhana basti treatment in the management of coronary artery disease (Hridroga)
por: Sharma, Amit Kumar, et al.
Publicado: (2012)

Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer
por: Chadha, Awalpreet S., et al.
Publicado: (2016)

Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP
por: Folprecht, Gunnar, et al.
Publicado: (2020)

Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)
por: Kurreck, A., et al.
Publicado: (2020)

Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
por: Luber, Birgit, et al.
Publicado: (2011)

Trends and Challenges in AIoT/IIoT/IoT Implementation
por: Hou, Kun Mean, et al.
Publicado: (2023)

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2010)

Efficacy of Bevacizumab-Capecitabine in Combination for the First-Line Treatment of Metastatic Breast Cancer
por: Dyar, Stephen, et al.
Publicado: (2011)

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
por: Lordick, F, et al.
Publicado: (2010)

S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma–final results of the randomized AIO MATEO phase II trial
por: Stocker, G., et al.
Publicado: (2023)

Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study
por: Javle, M, et al.
Publicado: (2009)

Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_e0eh8s448e9gtmf9vcrh54v6e7